人民财讯9月12日电，百洋医药（301015）9月12日晚间公告，近日，公司与济坤医药及其实际控制人签 署了《战略合作协议》，百洋医药投资方拟参与济坤医药本次增资扩股。同时，济坤医药及实际控制人 应积极推动公司现有股东转让其持有的部分股权至百洋医药投资方。各方同意并确认，济坤医药持有的 JK1033项目IPF适应症完成二期临床试验、且三期临床试验完成首例入组之后，百洋医药投资方具有以 合理的、双方议定的价格受让"JK1033项目权益"的权利。创新药JK1033项目是一种从中药单体及其衍 生物中提取并经高通量筛选及改构优化得到的抗纤维化小分子化合物，拟用于治疗特发性肺纤维化 (IPF)和进行性肺纤维化(PPF) ...

Core Viewpoint - Baiyang Pharmaceutical (301015.SZ) has signed a strategic cooperation agreement with Tianjin Jikun Pharmaceutical Technology Co., Ltd. to leverage mutual resource advantages and enhance its innovative drug pipeline [1][2] Group 1: Strategic Cooperation - The strategic cooperation agreement outlines the collaboration plan and rights of the parties involved [1] - Baiyang Pharmaceutical has the right to acquire the "JK1033 project rights" at a mutually agreed price once the project reaches a certain stage, which would expand its innovative drug pipeline [1] Group 2: JK1033 Project - The JK1033 project is an anti-fibrosis small molecule compound derived from traditional Chinese medicine, aimed at treating idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) [1] - The project has completed various studies, received clinical trial approval in China, and is set to start Phase I clinical trials in January 2025 [1] - JK1033 has a multi-target mechanism that can intervene in several key signaling pathways involved in pulmonary fibrosis, showing promising anti-fibrosis and anti-inflammatory effects [1] Group 3: Company Profiles - Jikun Pharmaceutical is an innovative drug development company with a focus on organ fibrosis, inflammation, and immune regulation, utilizing a dual-driven model of chemical and biological drugs [2] - Baiyang Pharmaceutical aims to optimize medical scenarios through technological innovation and has signed an agreement to acquire a 24% stake in Jikun Pharmaceutical, reinforcing its commitment to innovation and commercialization [2]

每经AI快讯，9月12日，百洋医药（301015）(301015.SZ)公告称，公司与天津济坤医药科技及其实际控 制人在青岛市市北区签署了《战略合作协议》，旨在发挥双方资源优势。协议包括合作方案、甲方权利 约定等内容，但具体合作内容尚需进一步协商确定。本次协议签署预计不会对公司本年度的经营业绩产 生重大影响，未来随着双方业务合作的进一步加深，将有利于提升公司的持续盈利能力，对公司业绩产 生积极影响。 ...

百洋医药公告，公司与济坤医药及其实际控制人签署了战略合作协议。根据协议，百洋医药拟参与济坤 医药增资扩股，预计将持有济坤医药24%的股权。此次合作旨在发挥双方的资源优势，拓展公司在创新 药领域的产品管线。协议预计不会对公司本年度的经营业绩产生重大影响，但将有利于提升公司的持续 盈利能力。 ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号： | 2025-079 | | --- | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | | 青岛百洋医药股份有限公司 关于签署战略合作协议的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、协议的生效条件：自各方盖章及其授权代表签章之日起生效。 2、协议的风险及不确定性：本次签署的《战略合作协议》仅为协议各方开 展合作达成的战略合作共识，具体合作内容尚需进一步协商确定，有关具体合作 安排及金额以最终正式签署的品种合作协议等正式交易文件为准，后续进展尚存 在不确定性。 3、协议履行对公司业绩的影响：本次《战略合作协议》的签署预计不会对 公司本年度的经营业绩产生重大影响，未来随着各方业务合作的进一步加深，将 有利于提升公司的持续盈利能力，对公司业绩产生积极影响。 一、本次协议签署概况 为发挥双方的资源优势，近日，青岛百洋医药股份有限公司（以下简称"公 司""百洋医药"）与天津济坤医药科技有限公司（以下简称"济坤医药 ...

Company Overview - Baiyang Pharmaceutical Co., Ltd. is located in Qingdao, Shandong Province, established on March 8, 2005, and listed on June 30, 2021 [1] - The company provides comprehensive commercialization solutions for pharmaceutical product manufacturers, including brand operation, wholesale distribution, and retail, with a focus on marketing solutions for branded pharmaceutical manufacturers [1] Financial Performance - As of June 30, 2025, Baiyang Pharmaceutical achieved a revenue of 3.751 billion yuan, representing a year-on-year growth of 4.36%, while the net profit attributable to shareholders decreased by 55.75% to 163 million yuan [2] - The company has distributed a total of 1.551 billion yuan in dividends since its A-share listing, with 1.201 billion yuan distributed over the past three years [3] Stock Performance - On September 12, Baiyang Pharmaceutical's stock price decreased by 2.01%, trading at 30.72 yuan per share, with a market capitalization of 16.147 billion yuan [1] - The stock has increased by 31.01% year-to-date, with a 13.11% rise over the last five trading days, 17.34% over the last 20 days, and 55.70% over the last 60 days [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 15% to 18,800, with an average of 27,926 circulating shares per shareholder, a decrease of 13.05% [2] - Among the top ten circulating shareholders, ICBC Frontier Medical Stock A (001717) ranked as the eighth largest, holding 2.6816 million shares, a decrease of 3.4767 million shares from the previous period [3] Market Position - Baiyang Pharmaceutical operates within the pharmaceutical and biological industry, specifically in the pharmaceutical commercial and distribution sector, and is associated with concepts such as online marketing, high dividends, and financing [2]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.29% on September 10, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) rising by 3.99% to a closing price of 28.70, and Dazhenglin (603233) falling by 2.37% to 17.30 [1][2] - Other notable gainers included Guofa Co. (600538) with a 1.65% increase and Dazhangzhang (002462) with a 1.22% increase [1] Trading Volume and Value - Seer Medical had a trading volume of 250,500 shares and a transaction value of 719 million yuan, while Dazhenglin had a trading volume of 77,200 shares and a transaction value of 134 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 11.87 million yuan from institutional investors and 50.86 million yuan from speculative funds, while retail investors contributed a net inflow of 62.74 million yuan [2] - Specific stocks like Seer Medical and Jiuzhoutong (600998) had significant net inflows from institutional investors, while others like Yifeng Pharmacy (603939) experienced net outflows from both institutional and speculative funds [3]

证券代码：301015 证券简称：百洋医药 公告编号：2025-078 债券代码：123194 债券简称：百洋转债 青岛百洋医药股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，为满足子公司业务发展的资金需求，青岛百洋医药股份有限公司（以下 简称"公司"）为全资子公司北京百洋智合医学成果转化服务有限公司（以下简称 "百洋智合"）的授信额度提供了连带责任保证担保。具体情况如下： 近日，为满足日常经营资金需求，百洋智合向招商银行股份有限公司北京分行 （以下简称"招商银行"）申请了综合授信额度。为支持子公司的业务发展，公司 出具了《最高额不可撤销担保书》，为上述授信额度提供连带责任保证担保，担保 授信本金余额最高限额为人民币 3,000 万元。本次担保事项在前述担保额度范围内， 无需另行召开董事会及股东大会审议。 本次担保前公司对百洋智合已提供且尚在担保期限内的担保余额为5,000万元； 本次担保后公司对百洋智合已提供且尚在担保期限内的担保余额为 6,010 万元，百 洋智合可用担保额度为 12,000 万元。 注： ...

Core Viewpoint - Zhongshan Leberich Biopharmaceutical Co., Ltd. has successfully completed an A++ round of financing, exceeding its fundraising target, with participation from several investors including Baiyang Pharmaceutical Group, Dongfang Morning Star, Saint No Biotech, and Chenghai Venture Capital [1] Group 1 - The financing round was led by Baiyang Pharmaceutical Group, with follow-on investments from Dongfang Morning Star, Saint No Biotech, and Chenghai Venture Capital [1] - Existing shareholder Zhuhai Yihai also increased its investment in this round [1] - The funds raised will primarily be used to advance pipeline projects RAB001d and RAB202, as well as to strengthen the company's technology platform and team development [1]

Market Overview - The pharmaceutical commercial sector increased by 1.96% on September 8, with Baiyang Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3826.84, up 0.38%, while the Shenzhen Component Index closed at 12666.84, up 0.61% [1] Stock Performance - Baiyang Pharmaceutical (301015) closed at 29.09, up 7.11% with a trading volume of 154,200 shares and a transaction value of 437 million yuan [1] - Yifeng Pharmacy (603939) closed at 26.18, up 5.27% with a trading volume of 186,100 shares and a transaction value of 478 million yuan [1] - Dazhenglin (603233) closed at 17.70, up 3.09% with a trading volume of 139,100 shares [1] - Other notable stocks include Renmintongtai (600829) up 2.76% and Jiuzhoutong (600998) up 2.23% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 124 million yuan from institutional investors, while retail investors saw a net inflow of 72.2 million yuan [2] - The sector's overall capital flow indicates a mixed sentiment among different investor types [2] Individual Stock Capital Flow - Baiyang Pharmaceutical had a net inflow of 47.64 million yuan from institutional investors, but a net outflow of 66.21 million yuan from retail investors [3] - Renmintongtai saw a net inflow of 8.94 million yuan from institutional investors, while retail investors had a net outflow of 707.48 million yuan [3] - Other stocks like Yixin Tang (002727) and Ruikang Pharmaceutical (002589) also showed varied capital flows, indicating differing investor sentiments [3]